{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T09:48:23Z","timestamp":1783158503214,"version":"3.54.6"},"reference-count":69,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9,5]]},"abstract":"<jats:p>Mefloquine (Lariam<jats:sup>\u00ae<\/jats:sup>; Roche Holding AG, Basel, Switzerland) has been linked to acute neuropsychiatric side effects. This is a concern for U.S. veterans who may have used mefloquine during recent Southwest Asia deployments. Using data from the <jats:italic>National Health Study for a New Generation of U.S. Veterans<\/jats:italic>, a population-based study of U.S. veterans who served between 2001 and 2008, we investigated associations between self-reported use of antimalarial medications and overall physical and mental health (MH) using the twelve-item short form, and with other MH outcomes using the post-traumatic stress disorder Checklist-17 and the Patient Health Questionnaire (anxiety, major depression, and self-harm). Multivariable logistic regression was performed to examine associations between health measures and seven antimalarial drug categories: any antimalarial, mefloquine, chloroquine, doxycycline, primaquine, mefloquine plus any other antimalarial, and any other antimalarial or antimalarial combination while adjusting for the effects of deployment and combat exposure. Data from 19,487 veterans showed that although antimalarial use was generally associated with higher odds of negative health outcomes, once deployment and combat exposure were added to the multivariable models, the associations with each of the MH outcomes became attenuated. A positive trend was observed between combat exposure intensity and prevalence of the five MH outcomes. No significant associations were found between mefloquine and MH measures. These data suggest that the poor physical and MH outcomes reported in this study population are largely because of combat deployment exposure.<\/jats:p>","DOI":"10.4269\/ajtmh.18-0107","type":"journal-article","created":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T07:00:54Z","timestamp":1529996454000},"page":"638-648","source":"Crossref","is-referenced-by-count":8,"title":["Associations between Use of Antimalarial Medications and Health among U.S. Veterans of the Wars in Iraq and Afghanistan"],"prefix":"10.4269","volume":"99","author":[{"given":"Aaron I.","family":"Schneiderman","sequence":"first","affiliation":[{"name":"Department of Veterans Affairs, Epidemiology Program, Post Deployment Health Services (10P4Q), Office of Patient Care Services, Veterans Health Administration, Washington, District of Columbia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin S.","family":"Cypel","sequence":"additional","affiliation":[{"name":"Department of Veterans Affairs, Epidemiology Program, Post Deployment Health Services (10P4Q), Office of Patient Care Services, Veterans Health Administration, Washington, District of Columbia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin K.","family":"Dursa","sequence":"additional","affiliation":[{"name":"Department of Veterans Affairs, Epidemiology Program, Post Deployment Health Services (10P4Q), Office of Patient Care Services, Veterans Health Administration, Washington, District of Columbia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Bossarte","sequence":"additional","affiliation":[{"name":"Department of Behavioral Medicine and Psychiatry, West Virginia University Injury Control Research Center, West Virginia University School of Medicine, Morgantown, West Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2795","reference":[{"key":"b1","series-title":"JAMA","first-page":"2251","article-title":"Controversies and misconceptions in malaria chemoprophylaxis for travelers","volume":"297","author":"Chen","year":"2007"},{"key":"b2","series-title":"Travel Med Infect Dis","first-page":"5","article-title":"Deaths and parasuicides associated with mefloquine chemoprophylaxis: a systematic review","volume":"20","author":"Tickell-Painter","year":"2017"},{"key":"b3","series-title":"Am J Prev Med","first-page":"194","article-title":"Self-reported adverse events associated with antimalarial chemoprophylaxis in Peace Corps volunteers","volume":"33","author":"Korhonen","year":"2007"},{"key":"b4","series-title":"Chemotherapy","first-page":"385","article-title":"Antimalarial drug toxicity: a review","volume":"53","author":"Alkadi","year":"2007"},{"key":"b5","series-title":"Drug Saf","first-page":"25","article-title":"Antimalarial drug toxicity: a review","volume":"27","author":"Taylor","year":"2004"},{"key":"b6","author":"Fukuda","year":"2017"},{"key":"b7","series-title":"Am J Trop Med Hyg","first-page":"587","article-title":"Compliance with antimalarial chemoprophylaxis in a combat zone","volume":"86","author":"Brisson","year":"2012"},{"key":"b8","author":"Department of Veterans Affairs, Epidemiology Program, Post-Deployment Health Group","year":"2017"},{"key":"b9","author":"Office of the Assistant Secretary of Defense for Health Affairs","year":"2009"},{"key":"b10","author":"Office of the Assistant Secretary of Defense for Health Affairs","year":"2013"},{"key":"b11","author":"Armed Forces Epidemiological Board","year":"2003"},{"key":"b12","author":"Armed Forces Epidemiological Board","year":"2004"},{"key":"b13","series-title":"Am J Trop Med Hyg","first-page":"517","article-title":"Doxycycline for malaria chemoprophylaxis and treatment: report from the CDC expert meeting on malaria chemoprophylaxis","volume":"84","author":"Tan","year":"2011"},{"key":"b14","series-title":"Am J Trop Med Hyg","first-page":"584","article-title":"Safety, tolerability, and compliance with long-term antimalarial chemoprophylaxis in American soldiers in Afghanistan","volume":"93","author":"Saunders","year":"2015"},{"key":"b15","series-title":"J Infect","first-page":"253","article-title":"The efficacy and tolerability of doxycycline and mefloquine in malaria prophylaxis of the ISAF troops in Afghanistan","volume":"51","author":"Sonmez","year":"2005"},{"key":"b16","series-title":"Trop Med Int Health","first-page":"919","article-title":"Tolerability of doxycycline monohydrate salt vs. chloroquine-proguanil in malaria chemoprophylaxis","volume":"7","author":"Pag\u00e8s","year":"2002"},{"key":"b17","series-title":"Intern Med J","first-page":"919","article-title":"Association of doxycycline use with the development of gastroenteritis, irritable bowel syndrome and inflammatory bowel disease in Australians deployed abroad","volume":"43","author":"Lee","year":"2013"},{"key":"b18","series-title":"Expert Opin Drug Saf","first-page":"571","article-title":"The use and safety of doxycycline hyclate and other second-generation tetracyclines","volume":"7","author":"Sloan","year":"2008"},{"key":"b19","series-title":"Ophthalmology","first-page":"110","article-title":"Pericentral retinopathy and racial differences in hydroxychloroquine toxicity","volume":"122","author":"Melles","year":"2015"},{"key":"b20","series-title":"J Travel Med","first-page":"S48","article-title":"Current drugs for antimalarial chemoprophylaxis: a review of efficacy and safety","volume":"8","author":"Jong","year":"2001"},{"key":"b21","series-title":"Clin Rev Allergy Immunol","first-page":"317","article-title":"A critical review of the effects of hydroxychloroquine and chloroquine on the eye","volume":"49","author":"Costedoat-Chalumeau","year":"2015"},{"key":"b22","series-title":"Interdiscip Perspect Infect Dis","first-page":"1","article-title":"Side effects of chloroquine and primaquine and symptom reduction in malaria endemic area (M\u00e2ncio Lima, Acre, Brazil)","volume":"2015","author":"Braga","year":"2015"},{"key":"b23","series-title":"Malar J","first-page":"418","article-title":"Primaquine: the risks and the benefits","volume":"13","author":"Ashley","year":"2014"},{"key":"b24","series-title":"Am J Trop Med Hyg","first-page":"402","article-title":"Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I","volume":"75","author":"Hill","year":"2006"},{"key":"b25","series-title":"Am J Trop Med Hyg","first-page":"86","article-title":"Neuropsychiatric side effects after the use of mefloquine","volume":"45","author":"Weinke","year":"1991"},{"key":"b26","series-title":"N Engl J Med","first-page":"1752","article-title":"Neuropsychiatric side effects of mefloquine","volume":"322","author":"St\u00fcrchler","year":"1990"},{"key":"b27","series-title":"BMJ","first-page":"1078","article-title":"Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study","volume":"327","author":"Schlagenhauf","year":"2003"},{"key":"b28","series-title":"Travel Med Infect Dis","first-page":"2","article-title":"Mefloquine toxicity: a literature review","volume":"7","author":"Toovey","year":"2009"},{"key":"b29","series-title":"Am J Trop Med Hyg","first-page":"159","article-title":"Neuropsychiatric outcomes after mefloquine exposure among US military service members","volume":"96","author":"Eick-Cost","year":"2017"},{"key":"b30","series-title":"Travel Med Infect Dis","first-page":"80","article-title":"Acute and long-term psychiatric side effects of mefloquine: a follow-up on Danish adverse event reports","volume":"13","author":"Ringqvist","year":"2015"},{"key":"b31","series-title":"Eur J Clin Pharmacol","first-page":"441","article-title":"Neuropsychiatric events during prophylactic use of mefloquine before travelling","volume":"58","author":"Van Riemsdijk","year":"2002"},{"key":"b32","series-title":"Clin Pharmacol Ther","first-page":"294","article-title":"Atovaquone plus chloroguanide versus mefloquine for malaria prophylaxis: a focus on neuropsychiatric adverse events","volume":"72","author":"Van Riemsdijk","year":"2002"},{"key":"b33","series-title":"J Clin Psychiatry","first-page":"199","article-title":"Mefloquine increases the risk of serious psychiatric events during travel abroad: a nationwide case-control study in the Netherlands","volume":"66","author":"Van Riemsdijk","year":"2005"},{"key":"b34","series-title":"Travel Med Infect Dis","first-page":"50","article-title":"Long term health outcomes among returned Peace Corps volunteers after malaria prophylaxis, 1995\u20132014","volume":"17","author":"Tan","year":"2017"},{"key":"b35","author":"Food and Drug Administration","year":"2013"},{"key":"b36","series-title":"Neuropharmacology","first-page":"1132","article-title":"Mefloquine inhibits cholinesterases at the mouse neuromuscular junction","volume":"49","author":"McArdle","year":"2005"},{"key":"b37","series-title":"J Trauma Stress","first-page":"542","article-title":"Prevalence of a positive screen for PTSD among OEF\/OIF and OEF\/OIF-Era veterans in a large population-based cohort","volume":"27","author":"Dursa","year":"2014"},{"key":"b38","series-title":"Am J Public Health","first-page":"1651","article-title":"Trends and risk factors for mental health diagnoses among Iraq and Afghanistan veterans using Department of Veterans Affairs health care, 2002\u20132008","volume":"99","author":"Seal","year":"2009"},{"key":"b39","series-title":"Mil Med","first-page":"374","article-title":"Health care utilization behavior of veterans who deployed to Afghanistan and Iraq","volume":"180","author":"Lee","year":"2015"},{"key":"b40","series-title":"Pharmacoepidemiol Drug Saf","first-page":"206","article-title":"Mefloquine prescriptions in the presence of contraindications: prevalence among US military personnel deployed to Afghanistan, 2007","volume":"19","author":"Nevin","year":"2010"},{"key":"b41","series-title":"Mil Med","first-page":"966","article-title":"The National Health Study for a new generation of United States veterans: methods for a large-scale study on the health of recent veterans","volume":"178","author":"Eber","year":"2013"},{"key":"b42","author":"Dillman","year":"2014"},{"key":"b43","series-title":"Case Rep Psychiatry","first-page":"1","article-title":"Severe neuropsychiatric reaction in a deployed military member after prophylactic mefloquine","volume":"2011","author":"Peterson","year":"2011"},{"key":"b44","series-title":"J Neuropsychiatry Clin Neurosci","first-page":"302","article-title":"Cognitive and neuropsychiatric side effects of mefloquine","volume":"13","author":"Javorsky","year":"2001"},{"key":"b45","series-title":"Trop Med Parasitol","first-page":"257","article-title":"Tolerability of prophylactic Lariam\u00ae regimens","volume":"44","author":"Boudreau","year":"1993"},{"key":"b46","series-title":"Expert Opin Drug Saf","first-page":"903","article-title":"Adverse neuropsychiatric effects of antimalarial drugs","volume":"15","author":"Grabias","year":"2016"},{"key":"b47","author":"Department of Defense (DoD)","year":"2003"},{"key":"b48","series-title":"Psychometrika","first-page":"297","article-title":"Coefficient alpha and the internal structure of tests","volume":"16","author":"Cronbach","year":"1951"},{"key":"b49","series-title":"Med Care","first-page":"220","article-title":"A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity","volume":"34","author":"Ware","year":"1996"},{"key":"b50","author":"Weathers","year":"1993"},{"key":"b51","series-title":"J Rehabil Res Dev","first-page":"465","article-title":"Psychometric properties of PTSD checklist in sample of male veterans","volume":"45","author":"Keen","year":"2008"},{"key":"b52","series-title":"JAMA","first-page":"1737","article-title":"Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study","volume":"282","author":"Spitzer","year":"1999"},{"key":"b53","author":"SAS Institute Inc","year":"2014"},{"key":"b54","author":"Yoon","year":"2013"},{"key":"b55","author":"Kuha","year":"1997"},{"key":"b56","series-title":"BMJ","first-page":"525","article-title":"Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers","volume":"313","author":"Barrett","year":"1996"},{"key":"b57","series-title":"Eur J Clin Pharmacol","first-page":"1","article-title":"Neuro-psychiatric effects of antimalarials","volume":"52","author":"Van Riemsdijk","year":"1997"},{"key":"b58","series-title":"Trop Med Int Health","first-page":"485","article-title":"Mefloquine tolerability during chemoprophylaxis: focus on adverse event assessments, stereochemistry and compliance","volume":"1","author":"Schlagenhauf","year":"1996"},{"key":"b59","series-title":"J Travel Med","first-page":"42","article-title":"Evaluation of mood profiles during malaria chemoprophylaxis: a randomized, double-blind, four-arm study","volume":"16","author":"Schlagenhauf","year":"2009"},{"key":"b60","series-title":"Ann Trop Med Parasitol","first-page":"639","article-title":"The relationship between body weight and tolerance to mefloquine prophylaxis in non-immune adults: results of a questionnaire-based study","volume":"98","author":"Ollivier","year":"2004"},{"key":"b61","series-title":"Am J Trop Med Hyg","first-page":"230","article-title":"Tolerance of mefloquine chemoprophylaxis in Dutch military personnel","volume":"55","author":"Jaspers","year":"1996"},{"key":"b62","series-title":"Travel Med Infect Dis","first-page":"71","article-title":"Antimalarial chemoprophylaxis and the risk of neuropsychiatric disorders","volume":"11","author":"Schneider","year":"2013"},{"key":"b63","series-title":"Am J Trop Med Hyg","first-page":"744","article-title":"Mefloquine use and hospitalizations among US service members, 2002\u20132004","volume":"74","author":"Wells","year":"2006"},{"key":"b64","series-title":"Lancet","first-page":"848","article-title":"Long-term malaria prophylaxis with weekly mefloquine","volume":"341","author":"Lobel","year":"1993"},{"key":"b65","series-title":"Travel Med Infect Dis","first-page":"5","article-title":"Prophylactic efficacy of primaquine for preventing Plasmodium falciparum and Plasmodium vivax parasitaemia in travelers: a meta-analysis and systematic review","volume":"17","author":"Kolifarhood","year":"2017"},{"key":"b66","series-title":"Trans R Soc Trop Med Hyg","first-page":"568","article-title":"Evaluation of the safety and tolerability of a short higher-dose primaquine regimen for presumptive anti-relapse therapy in healthy subjects","volume":"105","author":"Ebringer","year":"2011"},{"key":"b67","series-title":"Clin Infect Dis","first-page":"1502","article-title":"Primaquine as prophylaxis for malaria for nonimmune travelers: a comparison with mefloquine and doxycycline","volume":"29","author":"Schwartz","year":"1999"},{"key":"b68","series-title":"Clin Infect Dis","first-page":"1990","article-title":"Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia","volume":"33","author":"Baird","year":"2001"},{"key":"b69","series-title":"Malar J","first-page":"332","article-title":"Psychiatric effects of malaria and antimalarial drugs: historical and modern perspectives","volume":"15","author":"Nevin","year":"2016"}],"container-title":["The American Journal of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/99\/3\/article-p638.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/99\/3\/article-p638.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/99\/3\/article-p638.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T19:48:03Z","timestamp":1722455283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/99\/3\/article-p638.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,5]]},"references-count":69,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.18-0107","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"value":"0002-9637","type":"print"},{"value":"1476-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,5]]}}}